Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. (Q34064360)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Tamoxifen-induced severe hypertriglyceridemia and pancreatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

K Nakou

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Liamis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

N A Pavlidis

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

1067-1069

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

Tamoxifen, serum lipoproteins and cardiovascular risk

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

The Royal Marsden Hospital pilot tamoxifen chemoprevention trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Tamoxifen decreases lipoprotein (a) in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Severe lipemia induced by tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Fatal hyperlipaemia in a case of metastatic breast cancer treated by tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Delayed severe hypertriglyceridemia from tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Relation between apolipoprotein e phenotype and the changes in lipids during tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Effect of tamoxifen on serum lipid metabolism.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Secondary causes of hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008309613082

7 January 2021

Identifiers

DOI

10.1023/A:1008309613082

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11038048%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference